UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000016301 |
|---|---|
| Receipt number | R000018916 |
| Scientific Title | Multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide. |
| Date of disclosure of the study information | 2015/01/23 |
| Last modified on | 2020/04/06 11:13:51 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2015/01/22 10:19:42 | ||
| 2 | Update | 2015/06/01 16:59:14 | Public title Acronym |
|
| 3 | Update | 2015/06/01 17:01:24 | Key inclusion criteria Key inclusion criteria |
|
| 4 | Update | 2015/07/22 16:55:54 | Email |
|
| 5 | Update | 2015/11/12 18:01:34 | Recruitment status |
|
| 6 | Update | 2016/12/16 16:59:39 | Randomization unit Key exclusion criteria Key exclusion criteria |
|
| 7 | Update | 2016/12/16 17:03:38 | Name of primary person or sponsor Organization Secondary IDs Study ID_1 Org. issuing International ID_1 Org. issuing International ID_1 |
|
| 8 | Update | 2017/02/02 09:10:57 | Organization Organization |
|
| 9 | Update | 2019/01/24 11:35:15 | Recruitment status |
|
| 10 | Update | 2019/01/24 12:45:15 | UMIN ID1 |
|
| 11 | Update | 2019/01/24 13:42:33 | Recruitment status Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
| 12 | Update | 2020/04/06 10:30:17 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 13 | Update | 2020/04/06 10:57:13 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
| 14 | Update | 2020/04/06 11:12:14 | Results |
|
| 15 | Update | 2020/04/06 11:13:51 | Date of IRB Date analysis concluded |
